S Rossi1, C Rocchi2, V Studer1, C Motta1, B Lauretti2, G Germani1, G Macchiarulo1, G A Marfia2, D Centonze3. 1. Clinica Neurologica, Università Tor Vergata, Rome, Italy/Fondazione Santa Lucia, Centro Europeo per la Ricerca sul Cervello (CERC), Rome, Italy. 2. Clinica Neurologica, Università Tor Vergata, Rome, Italy. 3. Clinica Neurologica, Università Tor Vergata, Rome, Italy/Fondazione Santa Lucia, Centro Europeo per la Ricerca sul Cervello (CERC), Rome, Italy centonze@uniroma2.it.
Abstract
BACKGROUND: Predictive markers of cardiac side effects would be helpful for the stratification and individualized monitoring of multiple sclerosis (MS) patients prescribed with fingolimod. OBJECTIVE: To test whether the autonomic balance predicts a cardiac response after the first dose of fingolimod. METHODS: A total of 55 consecutive relapsing-remitting MS (RRMS) patients underwent 'head-up tilt', Valsalva maneuver, deep breathing and handgrip tests before their first dose of fingolimod. The normalized unit of the high frequency (HF) component (HF normalized units; HFnu), reflecting mostly vagal activity; and the low frequency (LF) component (LF normalized units; LFnu) reflecting mostly sympathetic activity, were considered for the analysis of heart rate (HR) variability. The patients' HR and electrocardiographic parameters ((the interval between P wave and ventricular depolarization (PR); the interval between Q and T waves (QT)) were recorded during 6-hour post-dose monitoring. RESULTS: We found significant correlations between measures of parasympathetic function and fingolimod-induced bradycardia. Subjects with higher Valsalva ratio and HR variation during deep breathing had, in fact, nadir HR ≤ 50 beats/minute (bpm) after the first fingolimod dose. Conversely, significant negative correlations were found between measures of sympathetic function and fingolimod-induced PR interval increase. Subjects with lower LFnu at rest and less increase of blood pressure on the handgrip test showed a PR interval increase > 20 ms after fingolimod. CONCLUSIONS: Assessing autonomic control of cardiovascular functions can be useful to predict cardiac effects after the first fingolimod dose.
BACKGROUND: Predictive markers of cardiac side effects would be helpful for the stratification and individualized monitoring of multiple sclerosis (MS) patients prescribed with fingolimod. OBJECTIVE: To test whether the autonomic balance predicts a cardiac response after the first dose of fingolimod. METHODS: A total of 55 consecutive relapsing-remitting MS (RRMS) patients underwent 'head-up tilt', Valsalva maneuver, deep breathing and handgrip tests before their first dose of fingolimod. The normalized unit of the high frequency (HF) component (HF normalized units; HFnu), reflecting mostly vagal activity; and the low frequency (LF) component (LF normalized units; LFnu) reflecting mostly sympathetic activity, were considered for the analysis of heart rate (HR) variability. The patients' HR and electrocardiographic parameters ((the interval between P wave and ventricular depolarization (PR); the interval between Q and T waves (QT)) were recorded during 6-hour post-dose monitoring. RESULTS: We found significant correlations between measures of parasympathetic function and fingolimod-induced bradycardia. Subjects with higher Valsalva ratio and HR variation during deep breathing had, in fact, nadir HR ≤ 50 beats/minute (bpm) after the first fingolimod dose. Conversely, significant negative correlations were found between measures of sympathetic function and fingolimod-induced PR interval increase. Subjects with lower LFnu at rest and less increase of blood pressure on the handgrip test showed a PR interval increase > 20 ms after fingolimod. CONCLUSIONS: Assessing autonomic control of cardiovascular functions can be useful to predict cardiac effects after the first fingolimod dose.
Authors: Sakari Simula; Tomi P Laitinen; Tiina M Laitinen; Päivi Hartikainen; Juha E K Hartikainen Journal: Ann Noninvasive Electrocardiol Date: 2017-02-13 Impact factor: 1.468
Authors: Sakari Simula; Tomi Laitinen; Tiina M Laitinen; Tuula Tarkiainen; Juha E K Hartikainen; Päivi Hartikainen Journal: J Neuroimmune Pharmacol Date: 2015-06-20 Impact factor: 4.147
Authors: Mario Habek; Luka Crnošija; Mila Lovrić; Anamari Junaković; Magdalena Krbot Skorić; Ivan Adamec Journal: Clin Auton Res Date: 2016-07-22 Impact factor: 4.435
Authors: Max J Hilz; Tassanai Intravooth; Sebastian Moeller; Ruihao Wang; De-Hyung Lee; Julia Koehn; Ralf A Linker Journal: PLoS One Date: 2015-07-06 Impact factor: 3.240
Authors: Aapo Laiho; Tiina M Laitinen; Päivi Hartikainen; Juha E K Hartikainen; Tomi P Laitinen; Sakari Simula Journal: Brain Behav Date: 2018-01-30 Impact factor: 2.708